The global glaucoma treatment market is anticipated to grow at a considerable CAGR of 5.2% during the forecast period (2021-2027). With the increasing prevalence of glaucoma among the geriatric population the demand for its treatment has been an increase. Therefore, the increasing approvals of the drugs for the treatment of glaucoma diseases are offering opportunities for market growth. For instance, in February 2021, Bausch health companies Inc., and Nicox, an ophthalmology company had received US FDA approval for VYZULTA, a latanoprostene bunod ophthalmic solution. This drug is for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma in the US. VYUZULTA is an important drug used for the treatment of glaucoma and now it is approved in nine markets including Canada, Argentina, Colombia, Taiwan, Hong Kong, Mexico, South Korea, Ukraine, and the US.
To Request a Sample of our Report on Glaucoma Treatment Market: https://www.omrglobal.com/request-sample/glaucoma-treatment-market
Further, in July 2019, Allergan Plc, a pharmaceutical company, has announced that the US Food and Drug Administration (FDA) has accepted the new drug application (NDA) for Bimatoprost sustained-release (SR). The NDA is focused on the promising outcomes of the ARTEMIS phase 3 trials, and it shows our continued commitment to developing alternative therapies for glaucoma patients. Apart from it, in September 2020, Aerie Pharmaceuticals Inc., an ophthalmic pharmaceutical company focused on drugs for the treatment of eye-related disease, has announced that FDA has approved a new drug application (NDA), and AR-15512 eye drop for dry eye. Thus, the huge US FDA approvals for glaucoma treatment and various initiatives in drugs by the companies for the treatment of disease are driving the global market growth during the forecast period.
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
Segment Covered-
- By Disease Indication
- By Distribution Channel
- By Drug Class
Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
- Competitive Landscape-Aeries Pharmaceuticals, Inc., Bausch & Lomb Inc., Inotek Pharmaceuticals, Novartis AG, Merck & Co., Pfizer Inc., Teva Pharmaceuticals Industries, Hoya Corp., and others
(Get 15% Discount on Buying this Report)
A full Report of Glaucoma Treatment Market is Available at: https://www.omrglobal.com/industry-reports/glaucoma-treatment-market
Recent Strategies initiatives in the Global Glaucoma Treatment Market:
- In November 2019, Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company focused on the treatment of patients with open-angle glaucoma, and other eye diseases announced that it has acquired AVizorex Pharma, S.L. (AVX). This acquisition was done for $10 million. This has expanded the drug portfolio of the company for the treatment of eye disease.
- In October 2018, Carl Zeiss Meditec has acquired IanTech, the company focused on technology solutions for micro-interventional cataract surgery. The company has enhanced the portfolio of surgical ophthalmology solutions, and this acquisition has assisted the company to provide ophthalmology solutions across the globe.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How COVID-19 impacted the market?
- Deviation from the pre-COVID-19 forecast
- Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Glaucoma Treatment Market Report Segment
By Disease Indication
- Closed Angle Glaucoma (CAG)
- Open-Angle Glaucoma (OAG)
- Secondary Glaucoma
- Congenital Glaucoma
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- By Drug Class
- Prostaglandin Analogues
- Alpha Agonist
- Cholinergic
- Beta-Blockers
- Carbonic Anhydrase Inhibitors
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
